Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16213346 | 0.84 | CA1 (0.54) | CA12CA2CA9CA1KMT2A | |
| SCHEMBL17503637 | 0.84 | CA1 (0.54) | CA12CA2CA9CA1KMT2A | |
| SCHEMBL28104760 | 0.84 | CA12 (0.50) | CA12CA2CA9CA1ATM | |
| SCHEMBL16884985 | 0.82 | CA12 (0.51) | CA12CA2CA9CA1KMT2A | |
| SCHEMBL12587896 | 0.82 | ATM (0.55) | CA12CA2CA9CA1KMT2A | |
| SCHEMBL20534352 | 0.80 | ATM (0.43) | CA12CA2CA9CA1ATM | |
| SCHEMBL1200588 | 0.80 | CA1 (0.53) | CA12CA2CA9CA1LMNA | |
| SCHEMBL5281607 | 0.80 | KMT2A (0.47) | CA12CA2CA9CA1KMT2A | |
| SCHEMBL23049597 | 0.80 | CA2 (0.44) | CA12CA2CA9CA1ATM | |
| SCHEMBL21992833 | 0.80 | ALDH1A1 (0.51) | CA12CA2CA9CA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270709-A1 | ANTIVIRAL PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION | CHRISTIAN-ALBRECHTS-UNIVERSITAT ZU KIEL (DE) | 2023-08-31 | — | — | US | disclosed |
| US-7101892-B2 | Sulfone derivatives as 5-HT7 receptor ligands | MERCK SHARP & DOHME LTD. | 2006-09-05 | — | — | US | disclosed |
| US-20040229864-A1 | Sulfone derivatives as 5-HT7 receptor ligands | MERCK SHARP & DOHME LTD. (GB) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229864-A1 | Sulfone derivatives as 5-HT7 receptor ligands | HTR7, HTR2C, HTR1A | CA12 4587/4885CA2 2094/4885CA9 4488/4885 |
| US-20230270709-A1 | ANTIVIRAL PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION | SPINT2, CTSG, SERPINB1 | CA12 2462/4885CA2 3065/4885CA9 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.